Compass Pathways PLC (CMPS) Stock AnalysisCMPSCompass Pathways PLC

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Compass Pathways PLC (CMPS) is not a strong buy due to its recent performance and financial instability. The current price is $12, and the RSI is at 42.63, indicating a neutral momentum. The forward P/E ratio is 0, reflecting uncertainty in future earnings, while the gross margin is not provided, suggesting a lack of profitability. The stock has seen a significant year-to-date change of +83.21%, but it has also experienced a 20-day change of -16.38%, indicating recent volatility. The main risk is the company's negative net income, which reached -253,794,000 USD in Q2 2026, raising concerns about its financial health and sustainability.